Early developments in gene-expression profiling of breast tumors: Potential for increasing black-white patient disparities in breast cancer outcomes?

Personalized Medicine

Volumn 8, Issue 6, 2011, Pages 669-679

  Odierna, Donna H ^b   Afable Munsuz, Aimee ^a   Ikediobi, Ogechi ^b   Beattie, Mary ^b   Knight, Sara ^b   Ko, Michelle ^c   Wilson, Adrienne ^b   Ponce, Ninez A ^c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African American women; breast cancer mortality; gene expression profiling; personalized medicine; racial disparities; social determinants of health

Indexed keywords

AFRICAN AMERICAN; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CAUCASIAN; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; MORBIDITY; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SOCIAL ASPECT; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 80755125647     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.67     Document Type: Review

References (77)

1. Smigal C, Jemal A, Ward E et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J. Clin. 56(3), 168-183 (2006). (Pubitemid 43847927)
2. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res. Treat. 121(2), 281-292 (2010).
3. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J. Womens Health (Larchmt) 18(6), 883-893 (2009).
4. Dignam JJ. The ongoing search for the sources of the breast cancer survival disparity. J. Clin. Oncol. 24(9), 1326-1328 (2006). (Pubitemid 46621993)
5. Gerend MA, Pai M. Social determinants of Black-white disparities in breast cancer mortality: a review. Cancer Epidemiol. Biomarkers Prev. 17(11), 2913-2923 (2008).
6. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J. Clin. Oncol. 24(9), 1342-1349 (2006). (Pubitemid 46621996)
7. Dignam JJ. Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J. Clin. 50(1), 50-64 (2000). (Pubitemid 30072095)
8. Tehranifar P, Neugut AI, Phelan JC et al. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol. Biomarkers Prev. 18(10), 2701-2708 (2009).
9. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365(5), 395-409 (2011).
10. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001). (Pubitemid 32878711)
11. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003). (Pubitemid 36842560)
12. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
13. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100(18), 10393-10398 (2003). (Pubitemid 37071889)
14. Marchionni L, Wilson RF, Wolff AC et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann. Intern. Med. 148(5), 358-369 (2008). (Pubitemid 351665467)
15. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009).
16. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460), 671-679 (2005). (Pubitemid 40260888)
17. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356(3), 217-226 (2007). (Pubitemid 46143225)
18. Carlson R, Brown E, Burstein H et al. NCCN Task Force Report: adjuvant therapy for breast cancer. J. Natl Compr. Canc. Netw. 4(Suppl. 1), S1-S26 (2006).
19. Harbeck N, Jakesz R. St Gallen 2007. Breast Cancer Treatment Consensus Report. Breast Care 2(3), 130-134 (2007).
20. Asad J, Jacobson AF, Estabrook A et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am. J. Surg. 196(4), 527-529 (2008).
21. Toi M, Iwata H, Yamanaka T et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116(13), 3112-3118 (2010).
22. Chang JC, Makris A, Gutierrez MC et al. Gene expression patterns in formalin-fixed, paraffin embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res. Treat. 108(2), 233-240 (2007). (Pubitemid 351311356)
23. Jerevall PL, Brommesson S, Strand C et al. Exploring the two-gene ratio in breast cancer - independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res. Treat. 107(2), 225-234 (2007). (Pubitemid 350265690)
24. Ma X-J, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6), 607-616 (2004). (Pubitemid 38748922)
25. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14(16), 5158-5165 (2008).
26. Summers C, Saltzstein SL, Blair SL, Tsukamoto TT, Sadler GR. Racial/ethnic differences in early detection of breast cancer: a study of 250,985 cases from the California Cancer Registry. J. Women's Health 19(2), 203-207 (2010).
27. Swan J, Breen N, Graubard BI et al. Data and trends in cancer screening in the United States: results from the 2005 National Health Interview Survey. Cancer 116(20), 4872-4881 (2010).
28. Jones BA, Kasl SV, Curnen MG, Owens PH, Dubrow R. Can mammography screening explain the race difference in stage at diagnosis of breast cancer? Cancer 75(8), 2103-2113 (1995).
29. Hunter CP, Redmond CK, Chen VW et al. Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group. J. Natl Cancer Inst. 85(14), 1129-1137 (1993). (Pubitemid 23212279)
30. Polite B, Olopade OI. Breast cancer and race: a rising tide does not lift all boats equally. Persp. Biol. Med. 48(1), 166-175 (2005).
31. Huo D, Ikpatt F, Khramtsov A et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J. Clin. Oncol. 27(27), 4515-4521 (2009).
32. Lund MJ, Butler EN, Bumpers HL et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 113(3), 608-615 (2008).
33. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21), 2492-2502 (2006). (Pubitemid 43854964)
34. Morris GJ, Naidu S, Topham AK et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110(4), 876-884 (2007). (Pubitemid 47257667)
35. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br. J. Cancer 98(2), 277-281 (2008). (Pubitemid 351161260)
36. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 302(15), 1685-1692 (2009).
37. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. 109, 1721-1728 (2007).
38. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13(15), 4429-4434 (2007). (Pubitemid 47219710)
39. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer 45(Suppl. 1), 27-40 (2009).
40. Menashe I, Anderson WF, Jatoi I, Rosenberg PS. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J. Natl Cancer Instit. 101(14), 993-1000 (2009).
41. Lund MJ, Mosunjac M, Davis KM et al. 21-gene recurrence scores: Racial differences in testing, scores, treatment, and outcome. Cancer DOI: 10.1002/cncr.26180 (2011) (Epub ahead of print).
42. Short LJ, Fisher MD, Wahl PM et al. Disparities in medical care among commercially insured patients with newly diagnosed breast cancer. Cancer 116(1), 193-202 (2010).
43. Galea S, Tracy M, Hoggatt KJ, Dimaggio C, Karpati A. Estimated deaths attributable to social factors in the United States. Am. J. Public Health 101(8), 1456-1465 (2011).
44. Yu X. Socioeconomic disparities in breast cancer survival: relation to stage at diagnosis, treatment and race. BMC Cancer 9(1), 364 (2009).
45. Niu X, Pawlish K, Roche L. Cancer survival disparities by race/ethnicity and socioeconomic status in New Jersey. J. Health Care Poor Underserved 21, 144-160 (2010).
46. Rose DP, Vona-Davis L. Influence of obesity on breast cancer receptor status and prognosis. Expert Rev. Anticancer Ther. 9(8), 1091-1101 (2009).
47. Kwan ML, Kushi LH, Weltzien E et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 11(3), R31 (2009).
48. Epel ES, Blackburn EH, Lin J et al. Accelerated telomere shortening in response to life stress. Proc. Natl Acad. Sci. USA 101(49), 17312-17315 (2004). (Pubitemid 39627816)
49. Ma H, Zhou Z, Wei S et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE 6(6), e20466 (2011).
50. Haas JS, Brawarsky P, Iyer A, Fitzmaurice GM, Neville BA, Earle C. Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality. Cancer 117(18), 4267-4276 (2011).
51. Link BG, Northridge ME, Phelan JC, Ganz ML. Social epidemiology and the fundamental cause concept: on the structuring of effective cancer screens by socioeconomic status. Milbank Q. 76(3), 375-402 (1998). (Pubitemid 128459464)
52. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer 7(12), 937-948 (2007). (Pubitemid 350165853)
53. Via M, Gignoux CR, Roth LA et al. History shaped the geographic distribution of genomic admixture on the island of Puerto Rico. PLoS ONE 6(1), e16513 (2011).
54. Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K. Mammographic breast density and family history of breast cancer. J. Natl Cancer Instit. 95(7), 556-558 (2003). (Pubitemid 36511627)
55. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin. Cancer Res. 14(24), 7988-7999 (2008).
56. Buchen L. Missing the mark: why is it so hard to find a test to predict cancer? Nature 471, 428-432 (2011).
57. Bossuyt PM. The thin line between hope and hype in biomarker research. JAMA 305(21), 2229-2230 (2011).
58. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305(21), 2200-2210 (2011).
59. Quinn B. Personalized diagnostics: the struggle for position. Per. Med. 7(3), 263-273 (2010).
60. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326(7400), 1167-1170 (2003). (Pubitemid 36649048)
61. Habel LA, Shak S, Jacobs MK et al. A population based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
62. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006). (Pubitemid 46622311)
63. Mina L, Soule SE, Badve S et al. Predicting response to primary chemotherapy. Gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res. Treat. 103(2), 197-208 (2006).
64. Esteva FJ, Sahin AA, Cristofanilli M et al. Prognostic role of a multigene reverse transcriptase PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res. 11(9), 3315-3319 (2005). (Pubitemid 40627881)
65. Cobleigh MA, Tabesh B, Bitterman P et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res. 11(24 Pt 1), 8623-8631 (2005). (Pubitemid 43005909)
66. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23(29), 7265-7277 (2005). (Pubitemid 46202341)
67. Cronin M, Pho M, Dutta D et al. Measurement of gene expression in archival paraffin-embedded tissues. Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol. 164(1), 35-42 (2004). (Pubitemid 38364587)
68. Paik S, Shak S, Tang G. Risk classification of breast cancer patients by the recurrence score assay. Comparison to guidelines based on patient age, tumor size, and tumor grade. Presented at Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004 (Abstract 104).
69. Jansen MP, Sieuwerts AM, Look MP et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer. a retrospective study. J. Clin. Oncol. 25(6), 662-668 (2007). (Pubitemid 350002921)
70. Goetz MP, Suman VJ, Ingle JN et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res. 12(7 Pt 1), 2080-2087 (2006).
71. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355(6), 560-569 (2006). (Pubitemid 44200649)
72. Reid JF, Lusa L, De Cecco L et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J. Natl Cancer Inst. 97(12), 927-930 (2005). (Pubitemid 41417944)
73. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98(17), 1183-1192 (2006). (Pubitemid 44390989)
74. Glas AM, Floore A, Delahaye LJ et al. Converting a breast cancer microarray signature into a highthroughput diagnostic test. BMC Genomics 7, 278 (2006).
75. Espinosa E, Vara JA, Redondo A et al. Breast cancer prognosis determined by gene expression profiling. A quantitative reverse transcriptase polymerase chain reaction study. J. Clin. Oncol. 23(29), 7278-7285 (2005). (Pubitemid 46205951)
76. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002). (Pubitemid 35461656)
77. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002). (Pubitemid 34130608)